# Camrelizumab Combined With Apatinib for Recurrent Resistant GTN

> **NCT04047017** · PHASE2 · COMPLETED · sponsor: **Peking Union Medical College Hospital** · enrollment: 20 (actual)

## Conditions studied

- Gestational Trophoblastic Disease

## Interventions

- **DRUG:** Apatinib
- **DRUG:** Camrelizumab

## Key facts

- **NCT ID:** NCT04047017
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-08
- **Primary completion:** 2021-03-18
- **Final completion:** 2021-05-15
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2021-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04047017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04047017, "Camrelizumab Combined With Apatinib for Recurrent Resistant GTN". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04047017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*